Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.

Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K.

Transfusion. 2008 Aug;48(8):1676-84. doi: 10.1111/j.1537-2995.2007.01762.x.

PMID:
18503613
2.

Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.

Lin L, Conlan MG, Tessman J, Cimino G, Porter S.

Transfusion. 2005 Oct;45(10):1610-20. Review.

PMID:
16181212
3.

Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model.

Jordan CT, Saakadze N, Newman JL, Lezhava LJ, Maiers TT, Hillyer WM, Roback JD, Hillyer CD.

Transfusion. 2004 Aug;44(8):1159-65.

PMID:
15265119
4.

Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.

Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L.

Transfusion. 2006 Jul;46(7):1168-77.

PMID:
16836564
5.
6.
7.

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.

Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L.

Transfusion. 2004 Oct;44(10):1496-504.

PMID:
15383024
8.

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.

Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L.

Transfusion. 2005 Apr;45(4):580-90.

PMID:
15819680
9.

Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma.

Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA.

Transfusion. 2010 May;50(5):1019-27. doi: 10.1111/j.1537-2995.2009.02538.x. Erratum in: Transfusion. 2010 Jul;50(7):1594.

PMID:
20030791
10.

Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.

Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzel P, Conlan MG; SPRINT Study Group..

Transfusion. 2006 Apr;46(4):562-71.

PMID:
16584432
11.

Photosensitized inactivation of Plasmodium falciparum- and Babesia divergens-infected erythrocytes in whole blood by lipophilic pheophorbide derivatives.

Grellier P, Santus R, Mouray E, Agmon V, Mazière JC, Rigomier D, Dagan A, Gatt S, Schrével J.

Vox Sang. 1997;72(4):211-20.

PMID:
9228710
12.

Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.

Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW Jr, Stassinopoulos A.

Transfusion. 2007 Jun;47(6):1062-70.

PMID:
17524098
13.

Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA.

Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L.

Blood. 1998 Mar 15;91(6):2180-8.

14.
15.

Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.

Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC.

Transfusion. 2005 Sep;45(9):1459-63.

PMID:
16131378
16.

Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.

Wagner SJ, Skripchenko A, Myrup A, Awatefe H, Thompson-Montgomery D, Moroff G, Carmichael P, Lin L.

Transfusion. 2009 Apr;49(4):704-10. doi: 10.1111/j.1537-2995.2008.02040.x.

PMID:
19171001
17.

Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.

Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP.

Transfusion. 2008 Apr;48(4):697-705. doi: 10.1111/j.1537-2995.2007.01594.x.

PMID:
18194378
18.

Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates.

Bruchmüller I, Janetzko K, Bugert P, Mayaudon V, Corash L, Lin L, Klüter H.

Transfusion. 2005 Sep;45(9):1464-72.

PMID:
16131379
19.

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Klüter H.

Vox Sang. 2004 May;86(4):239-45.

PMID:
15144528
20.

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.

Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG; SPRINT Study Group..

Transfusion. 2005 Dec;45(12):1864-75.

PMID:
16371039

Supplemental Content

Support Center